Pfiz­er nabs fast OK for a new front­line lung can­cer drug as phar­ma gi­ant shows off its new R&D strat­e­gy

Pfiz­er CEO Ian Read got a lit­tle help from the FDA to­day in high­light­ing his re­cent pledge to re­ly on the late-stage pipeline for fu­ture rev­enue growth. The agency has stamped its ap­proval on da­comi­tinib, a ki­nase in­hibitor now head­ed for front­line du­ty against non-small cell lung can­cer.

The drug has a nar­row­ly de­fined role for cas­es in­volv­ing an EGFR ex­on 19 dele­tion or ex­on 21 L858R sub­sti­tu­tion mu­ta­tions. It will now be sold as Viz­im­pro.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER